Sarcoma Lung Metastases Treated with Percutaneous Radiofrequency Ablation: Results from 29 Patients

Palussière, Jean; Italiano, Antoîne; Descat, E.; Ferrón, S.; Cornélis, F.; Avril, A.; Brouste, Véronique; Bui, Binh

doi:10.1245/s10434-011-1806-0

Cited by 64 publications

(31 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…26 Prior to this in 2011, Palussiere et al 27 reported 1-and 3-year survival of 92.2% and 65.2%, respectively, with a median disease-free survival of 7 months.…”

Section: Pulmonary Metastasesmentioning

confidence: 99%

Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances

Smith¹,

Jennings²

2015

BJR

View full text Add to dashboard Cite

Lung ablation can be used to treat both primary and secondary thoracic malignancies. Evidence to support its use, particularly for metastases from colonic primary tumours, is now strong, with survival data in selected cases approaching that seen after surgery. Because of this, the use of ablative techniques (particularly thermal ablation) is growing and the Royal College of Radiologists predict that the number of patients who could benefit from such treatment may reach in excess of 5000 per year in the UK. Treatment is often limited to larger regional centres, and general radiologists often have limited awareness of the current indications and the techniques involved. Furthermore, radiologists without any prior experience are frequently expected to interpret post-treatment imaging, often performed in the context of acute complications, which have occurred after discharge. This review aims to provide an overview of the current indications for pulmonary ablation, together with the techniques involved and the range of post-procedural appearances.

show abstract

“…26 Prior to this in 2011, Palussiere et al 27 reported 1-and 3-year survival of 92.2% and 65.2%, respectively, with a median disease-free survival of 7 months.…”

Section: Pulmonary Metastasesmentioning

confidence: 99%

Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances

Smith¹,

Jennings²

2015

BJR

View full text Add to dashboard Cite

show abstract

“…The 3-year survival rate was 65.2% (95% CI 0.42–0.81) with a median disease-free survival of 7 months. Although no major complications were reported, 68.7% of patients did develop a pneumothorax from the procedure with half requiring intervention [44]. …”

Section: Adjunctive Therapiesmentioning

confidence: 99%

Management of Sarcoma Metastases to the Lung

Digesu

Wiesel

Vaporciyan

et al. 2016

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

Synopsis Pulmonary metastases are a common manifestation of sarcoma that requires special attention. For decades, surgical resection of pulmonary metastases has been performed, and despite limited randomized data, surgery is increasingly accepted as an integral part in the management of metastatic disease. Although sarcoma is heterogeneous, common prognostic factors have been identified to guide surgeons prior to pulmonary metastasectomy including long disease-free interval, ability to obtain a complete resection, and extra-pulmonary disease control. Patients with adequate pulmonary reserve may undergo resection via thoracotomy or in select cases video-assisted thoracoscopic surgery (VATS). Long-term results indicate resection is potentially curative with significantly improved survival following complete resection. Recurrence, however, is not uncommon with many patients undergoing repeat resection. With advancing surgical technique and adjuvant therapies, patients with high or recurrent tumor burden are increasingly afforded disease control and potential cure. In this review, the prognostic characteristics of pulmonary metastases from sarcoma, pre-operative evaluation, operative technique, long-term outcomes, and management of complex patients are highlighted.

show abstract

“…There are also suggestions of the benefit of surgery for the metastases of soft tissue sarcomas [9,10], which result in long survival times in selected cases [11]. Currently, surgery has the highest level of evidential support regarding the ablation of limited metastases due to reports of cured patients with lung [12], hepatic [13], adrenal [14] and brain [15] metastases; thus, fewer, less-invasive, nonsurgical ablative modalities, including radiotherapy [16] and radiofrequency ablation (RFA), have been developed over the last 20 years [17].…”

Section: Introductionmentioning

confidence: 99%

Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group

et al. 2015

Self Cite

View full text Add to dashboard Cite

Sarcoma Lung Metastases Treated with Percutaneous Radiofrequency Ablation: Results from 29 Patients

Abstract: RFA is safe and efficient in the treatment of lung metastasis originating from sarcomas. RFA may provide a low-morbidity alternative to surgery, being less invasive and preserving the patient's ability to undergo possible repeat operations.

Cited by 64 publications

References 33 publications

Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances

Lung radiofrequency and microwave ablation: a review of indications, techniques and post-procedural imaging appearances

Management of Sarcoma Metastases to the Lung

Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group

Contact Info

Product

Resources

About